A 24‐week course of high‐dose interferon‐α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near‐normal alanine aminotransferase levels
A 24‐week course of high‐dose interferon‐α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near‐normal alanine aminotransferase levels
复制标题
针对谷丙转氨酶水平持续正常或接近正常的台湾慢性丙型肝炎患者进行 24 周大剂量干扰素 α 联合利巴韦林疗程
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
W. Chuang
中科院分区：
文献类型：
--
作者：
Ming‐Lung Yu;C. Dai;Li‐Po Lee;Nei‐Jen Hou;Ming‐Yen Hsieh;Jee‐Fu Huang;Zu;Shinn;M. Hsieh;L. Wang;W. Chang;W. Chuang
摘要：背景/目标：我们的目的是评估高剂量干扰素-α（INF-α; 600万单位，每周三次）联合利巴韦林（1000-1200 mg/天）治疗46例丙氨酸氨基转移酶（PNALT）水平持续正常或接近正常的台湾慢性丙型肝炎（CHC）患者的24周方案的疗效、优势和安全性。研究方法：92名年龄和性别匹配的CHC患者ALT水平升高（>正常范围上限的2倍），比例为1：2，接受相同方案治疗，作为对照。结果如下：PNALT组（67.4%）和ALT升高组（65.2%）的持续病毒学应答（SVR）率相当（意向治疗分析）。两组的停药率和不良反应发生率相似。病毒基因型1b、基线病毒载量、体重指数和年龄是与SVR呈负相关的显著因素。在PNALT组的持续应答者中观察到整个随访期间ALT水平进一步下降。8例ALT发作的患者均未发生黄疸型肝炎。在3年的延长随访期内维持了病毒学疗效。结论：高剂量INF-α联合利巴韦林治疗PNALT水平的CHC患者有效、安全且耐受性良好。ALT测定不能用作确定治疗考虑的单一生化标志物。
Abstract: Background/Aims: We aimed to evaluate the efficacy, advantage, and safety of a 24‐week regimen with high‐dose interferon‐α (INF‐α; 6 million units thrice weekly) plus ribavirin (1000–1200 mg/day) combination therapy for 46 Taiwanese chronic hepatitis C (CHC) patients with persistently normal or near‐normal alanine aminotransferase (PNALT) levels. Methods: Ninety‐two age‐ and sex‐matched CHC patients with elevated ALT levels (>2 times the upper limit of normal range) with a ratio of 1:2, treated with the same regimen, served as a control. Results: The sustained virologic response (SVR) rate was comparable between PNALT (67.4%) and elevated ALT (65.2%) groups (intention‐to‐treat analysis). The two groups had similar rates of discontinuation and incidence of adverse effects. Viral genotype 1b, baseline viral loads, body mass index, and age were significant factors negatively associated with SVR. Further decline of ALT levels throughout the follow‐up period was observed in sustained responders of the PNALT group. None of the eight patients with ALT flares developed icteric hepatitis. The virologic efficacy was sustained in a 3‐year extended follow‐up period. Conclusion: high‐dose INF‐α with ribavirin combination therapy is effective, safe, and well tolerated in CHC patients with PNALT levels. The ALT assay might not be used as a single biochemical marker for determination of treatment consideration.
影响因子：
158.5
作者：
McHutchison, JG;Gordon, SC;Albrecht, JK
通讯作者：
Albrecht, JK
DOI：
--
发表时间：
2002
期刊：
NIH consensus and state-of-the-science statements
影响因子：
--
作者：
通讯作者：
--
影响因子：
158.5
作者：
Fried, MW;Shiffman, ML;Yu, J
通讯作者：
Yu, J